A different tandem CAR-T cell targeted EGFRvIII and IL-13Rα2 and showed improved antitumor effects when targeting both antigens simultaneously in heterogeneous GBM.59 One group expanded on this concept by designing a trivalent CAR-T cell to target 3 antigens: HER2, IL-13Rα2, and ephrin-A2 (EphA2).60 The authors used flow cytometry for 15 primary GBM samples to highlight the inter-patient heterogeneity for these antigens. The gene discussed is IL13RA2; the disease is glioblastoma.